Skip to content

Hurry Up and Slow Down (Once Again)

May 22, 2020

It been a decade since we have experienced the much-vaunted but rarely-seen “regular order appropriations” (explained here). Instead, the slow, halting progress of appropriations bills has become the norm. … READ MORE …

Advocacy at Glance

May 22, 2020

Top-Line: FY 21 appropriations in the House and Senate are impeded by a range of roadblocks. These are discussed here, as well as in the Analysis and Commentary section. VA funding, which loomed as an additional impediment, looks to be resolved. … READ MORE …

How H.R. 6800 Might Impact the FDA

May 15, 2020

Sometimes legislation that is described as “dead on arrival” is truly without consequence. Other times, the effort to set a legislative position is highly meaningful, even if the bill itself is never going to become law. … READ MORE …

Advocacy at a Glance

May 15, 2020

Top-line: The House is expected to pass a resolution permitting virtual mark-ups during certain national emergencies. That should unlock the House appropriations process. The Senate appears to be making progress but still has not set out a pathway for consideration of appropriations bills. The House is expected to pass the next massive coronavirus legislation, which contains a number of provisions involving FDA. This is a preview of what legislation might look like, but any comparable Senate bill will be quite different. … READ MORE …

The Frieden Health Defense Funding Proposition

May 8, 2020

Congress is starting to consider ways to address the budget cap problem that hangs over the entire FY 21 appropriations process for non-defense discretionary (NDD) programs. … READ MORE …

Advocacy at a Glance

May 8, 2020

Top-line: Congress is inching forward on the FY 21 appropriations process. However, neither the House nor the Senate has adopted rules permitting virtual committee mark-ups. Also hanging over the process is the tight budget ceiling for non-defense discretionary (NDD) programs. Various ways it might be solved and implications for FDA are discussed in this week’s Analysis and Commentary. … READ MORE …

No Need for a Crystal Ball in Some Scenarios

May 1, 2020

FDA — along with NIH, CDC, and other front-line public health agencies — is caught up in the urgent COVID-19 efforts. Appropriately, enormous resources are being devoted to fighting the pandemic and more funding will come, if needed. … READ MORE …